ライフサイエンスコーパス: National Cancer Institute

1 Criteria for Adverse Events, grades 3 to 5 (National Cancer Institute).

2 University of Washington and National Cancer Institute.

3 ins University Center for AIDS Research, and National Cancer Institute.

4 Primary Funding Source: The National Cancer Institute.

5 coordinating center funded by the NHGRI and National Cancer Institute.

6 itute of Allergy and Infectious Diseases and National Cancer Institute.

7 ency for Healthcare Research and Quality and National Cancer Institute.

8 ational Heart, Lung, and Blood Institute and National Cancer Institute.

9 for Healthcare Research and Quality, and the National Cancer Institute.

10 National Institutes of Health National Cancer Institute.

11 ernational Breast Cancer Study Group, and US National Cancer Institute.

12 UK, the UK Department of Health, and the US National Cancer Institute.

13 National Institutes of Health/National Cancer Institute.

14 nnings in 1937 with the establishment of the National Cancer Institute.

15 MD Anderson Cancer Center, National Cancer Institute.

16 US National Institutes of Health/National Cancer Institute.

17 US National Institutes of Health and National Cancer Institute.

18 abetes and Digestive and Kidney Diseases and National Cancer Institute.

19 ty, US National Institutes of Health, and US National Cancer Institute.

20 Harvard T H Chan School of Public Health and National Cancer Institute.

21 d Surveillance Modeling Network) Lung Group, National Cancer Institute.

22 dation and the National Institutes of Health/National Cancer Institute.

23 Zelenetz), and National Institutes of Health/National Cancer Institute.

24 cale methods, with the support of the French National Cancer Institute.

25 l Research Trust, EU COST Action, and the US National Cancer Institute.

26 y and the Intramural Research Program of the National Cancer Institute.

27 more than two hundred types according to the National Cancer Institute.

28 logy, and End Results (SEER) database of the National Cancer Institute.

29 onally, a gene expression analysis using the National Cancer Institute 60 cell line panel identified

30 008, a WT-GIST clinic was established at the National Cancer Institute, allowing the development of a

31 National Cancer Institute, American Cancer Society, Agen

32 National Cancer Institute, American Lebanese Syrian Asso

33 National Institute of Mental Health, National Cancer Institute, American Lebanese Syrian Asso

34 US National Cancer Institute, American Lebanese Syrian Asso

35 National Cancer Institute, American Lebanese-Syrian Asso

36 National Cancer Institute, American Lebanese-Syrian Asso

37 ancer epidemiology research supported by the National Cancer Institute and a selected sample of the c

38 National Cancer Institute and Adaptive Biotechnologies.

39 National Cancer Institute and American Lebanese-Syrian A

40 US National Cancer Institute and AstraZeneca Pharmaceutical

41 National Cancer Institute and Centers for Disease Contro

42 NIAID, National Cancer Institute and Clinical Center Intramural

43 of Allergy and Infectious Diseases (NIAID), National Cancer Institute and Clinical Center Intramural

44 Paul Pinsky of the US National Cancer Institute and colleagues describe the im

45 US National Cancer Institute and ECOG-ACRIN Cancer Research

46 National Cancer Institute and Enzon Pharmaceuticals.

47 Patients were classified according to National Cancer Institute and FDA criteria, and the rate

48 US National Cancer Institute and Massachusetts General Hosp

49 National Cancer Institute and National Comprehensive Can

50 In 2018, the National Cancer Institute and NRG Oncology partnered for

51 zed cancer epidemiology grants funded by the National Cancer Institute and published literature for 2

52 by Developmental Therapeutic Program at the National Cancer Institute and represented promising cand

53 National Cancer Institute and Sanofi-Aventis.

54 US National Cancer Institute and the American Lebanese Syri

55 The National Cancer Institute and the US Food and Drug Admin

56 a computer encrypted numbering system at the National Cancer Institute) and became open-label when ea

57 from the AIDS and Cancer Specimen Resource (National Cancer Institute) and Johns Hopkins Hospital in

58 en and Children's Health Research Institute, National Cancer Institute, and American Lebanese Syrian

59 US National Institutes of Health, National Cancer Institute, and Amgen.

60 nstitute of Allergy and Infectious Diseases, National Cancer Institute, and Clinical Center Intramura

61 ous Diseases, National Institutes of Health, National Cancer Institute, and Gilead Sciences.

62 Jabbs Foundation (Birmingham, UK), US National Cancer Institute, and Henry J Predolin Foundati

63 lege of Surgeons Commission on Cancer or the National Cancer Institute, and quality measure reporting

64 Institut Bergonie; French National Cancer Institute; Association pour la Recherche

65 US National Cancer Institute, AstraZeneca Pharmaceuticals.

66 Italiana per la Ricerca sul Cancro, and the National Cancer Institute at the National Institutes of

67 osis was 5 years; 68% were boys; and 43% had National Cancer Institute-based high-risk disease.

68 absolute risk of BC >/= 1.66% (based on the National Cancer Institute BC Risk Assessment Tool or an

69 Recently, the National Cancer Institute began exploring opportunities

70 xcellent yields (94-99%) and screened by the National Cancer Institute (Bethesda, MD) on about 60 hum

71 -arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA).

72 re reviewed in patients with melanoma at the National Cancer Institute between January 1, 1953, and D

73 ogistic regression models with data from the National Cancer Institute Breast and Prostate Cancer Coh

74 , costs, and health state utilities from the National Cancer Institute Breast Cancer Surveillance Con

75 US National Institutes of Health, National Cancer Institute, Breast Cancer Research Founda

76 National Institutes of Health, National Cancer Institute, Bristol Myers Squibb, Celgene

77 cer Center Leukaemia SPORE CA100632 from the National Cancer Institute, Bristol Myers Squibb.

78 Exelixis, National Institutes of Health and National Cancer Institute Cancer Center Support Grant P3

79 s with advanced cancer were recruited from a National Cancer Institute cancer center, a Veterans Admi

80 2013, 207 patients with advanced cancer at a National Cancer Institute cancer center, a Veterans Affa

81 y Limited, and National Institutes of Health National Cancer Institute Cancer Center.

82 nstitutional breast MR examinations from the National Cancer Institute Cancer Imaging Archive, along

83 A National Cancer Institute Cancer Therapy Evaluation Prog

84 National Cancer Institute Cancer Therapy Evaluation Prog

85 National Cancer Institute (Cancer Therapy Evaluation Pro

86 cers, and the National Institutes of Health (National Cancer Institute) Cancer Center Support Grant.

87 nadian Cancer Society Research Institute, US National Cancer Institute, Cancer Council Australia, Roy

88 s corresponding to 69 proteins across all 60 National Cancer Institute cell lines in biological tripl

89 ntive Oncology, in collaboration with the US National Cancer Institute Center for Global Health, held

90 h review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeti

91 reatment-related adverse events according to National Cancer Institute Common Terminology Criteria fo

92 Adverse events were graded according to the National Cancer Institute Common Terminology Criteria fo

93 points were acute toxicity according to the National Cancer Institute Common Terminology Criteria fo

94 Toxic effects are reported using National Cancer Institute Common Terminology Criteria fo

95 the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria fo

96 The National Cancer Institute Common Terminology Criteria fo

97 The National Cancer Institute Common Terminology Criteria fo

98 These were documented in agreement with the National Cancer Institute Common Terminology Criteria fo

99 s, classified adverse events (AEs) using the National Cancer Institute Common Terminology Criteria fo

100 Toxicities were scored by using National Cancer Institute Common Toxicity Criteria 2.0 a

101 tively collected by investigators (graded by National Cancer Institute Common Toxicity Criteria [vers

102 Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale

103 ported acute and 6-month toxic effects using National Cancer Institute Common Toxicity Criteria, and

104 Toxicity was evaluated using National Cancer Institute Common Toxicity Criteria, vers

105 e toxicity rate was defined according to the National Cancer Institute Common Toxicity Criteria.

106 tinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria fo

107 mprove early-detection biopsy decisions, the National Cancer Institute conducted a prospective valida

108 The National Cancer Institute conducted the Biospecimen Pre-

109 The US National Cancer Institute convened a meeting to review p

110 Rectal-Anal Task Forces of the United States National Cancer Institute convened a panel of multidisci

111 Recently, the National Cancer Institute convened a Strategic Workshop

112 n of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discus

113 DLBCL (stages II-IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA).

114 uropathy was assessed at clinic visits using National Cancer Institute criteria and prospectively gra

115 risk groups on the basis of a combination of National Cancer Institute criteria, cytogenetics, and ea

116 standard- or high-risk disease according to National Cancer Institute criteria.

117 ritis and Musculoskeletal and Skin Diseases, National Cancer Institute, Damon Runyon Cancer Research

118 nal Heart, Lung, and Blood Institute and the National Cancer Institute, Danish Cancer Society, Novo N

119 ed naphthalenesulfonic acid library from the National Cancer Institute database, we identified small

120 eral nonhydroxamate compounds, obtained from National Cancer Institute database, which potentially in

121 against US Food and Drug Administration and National Cancer Institute databases of approved indicati

122 In this issue of Blood, Nicolae et al at the National Cancer Institute describe a series of Epstein-B

123 e interval [CI], 0.57-0.77), being seen at a National Cancer Institute-designated cancer center (HR,

124 esenting for surgical evaluation at a single National Cancer Institute-designated cancer center withi

125 ategorized into 3 mutually exclusive groups: National Cancer Institute-Designated Cancer Centers (NCI

126 cytoreductive surgery and chemotherapy at 6 National Cancer Institute-designated cancer centers betw

127 to IV ovarian cancer who were treated at six National Cancer Institute-designated cancer centers.

128 prequalify imaging facilities at all of the National Cancer Institute-designated comprehensive and c

129 ed institutional database was conducted at a National Cancer Institute-designated comprehensive cance

130 gastric cancer surgery database at a single National Cancer Institute-designated comprehensive cance

131 and outpatient surgical oncology unit of one National Cancer Institute-designated comprehensive cance

132 cal outcomes were collected and studied at a National Cancer Institute-designated comprehensive cance

133 ncluded patients who were being treated at a National Cancer Institute-designated comprehensive cance

134 etween July 3, 2014, and June 30, 2015, at a National Cancer Institute-designated comprehensive cance

135 , medical oncologists affiliated with the 40 National Cancer Institute-designated comprehensive cance

136 Physicians at a tertiary-care National Cancer Institute-designated comprehensive cance

137 smokers recently diagnosed with cancer in 2 National Cancer Institute-designated Comprehensive Cance

138 PET/CT scanners from 4 institutions (2 in a National Cancer Institute-designated Comprehensive Cance

139 erspective into adverse event reporting, the National Cancer Institute developed a patient-reported o

140 The National Cancer Institute developed the Centers for Quan

141 ased on available structures with use of the National Cancer Institute diversity set and a panel of D

142 Through virtual screening of the National Cancer Institute Diversity Set II and in vitro

143 The National Cancer Institute estimates that $154 billion wi

144 onal Health and Medical Research Council, US National Cancer Institute, European Organisation for Res

145 UK Medical Research Council, National Cancer Institute, European Science Foundation,

146 National Institutes of Health, National Cancer Institute, FDA Center for Tobacco Produc

147 of added sugars were identified by using the National Cancer Institute food categories.

148 and End Results (SEER) 18 registry from the National Cancer Institute for all PMCTs diagnosed from 1

149 Department for International Development UK, National Cancer Institute, Frederick National Laboratory

150 a National Heart, Lung, and Blood Institute/National Cancer Institute-funded Blood and Marrow Transp

151 t imaging registries that participate in the National Cancer Institute-funded Breast Cancer Surveilla

152 construction Outcomes Consortium Study is an National Cancer Institute-funded longitudinal, prospecti

153 The National Cancer Institute Genomic Data Commons (GDC) is

154 itution.FUNDINGNIH grant P01 CA23766 and NIH/National Cancer Institute grant P30 CA008748.

155 made in developing microbial therapies, the National Cancer Institute has for the first time issued

156 The National Cancer Institute has played an increasingly imp

157 Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Can

158 .5 times greater than dollars awarded by the National Cancer Institute in 2000.

159 es and Digestive and Kidney Diseases and the National Cancer Institute in 2015 to undertake collabora

160 ute of Environmental Health Sciences and the National Cancer Institute in conjunction with the annual

161 , PATH, the Peruvian Ministry of Health, the National Cancer Institute in Lima, and the Regional Canc

162 nal Agency for Research on Cancer and the US National Cancer Institute in September, 2013.

163 y concurrently from 2007 through 2014 at the National Cancer Institute in the United States.

164 search Center for Radiation Medicine, the US National Cancer Institute, in 2014-2018, initiated a gen

165 K, Tehran University of Medical Sciences, US National Cancer Institute, International Agency for Rese

166 National Cancer Institute Intramural Program and the Can

167 The National Cancer Institute Intramural Research Program.

168 The US National Cancer Institute is already implementing some o

169 National Cancer Institute, Korea Health Technology R&D P

170 earch Council, Cancer Australia, Sarcoma UK, National Cancer Institute, Liddy Shriver Sarcoma Initiat

171 ute of Texas, Leukemia and Lymphoma Society, National Cancer Institute, MD Anderson Cancer Center.

172 usual dietary intakes of folate by using the National Cancer Institute method to adjust two 24-h diet

173 beverages were obtained with the use of the National Cancer Institute method.

174 by Hispanic and Latino backgrounds by using National Cancer Institute methodology.

175 The National Cancer Institute Molecular Analysis for Therapy

176 The National Cancer Institute Molecular Analysis for Therapy

177 Here, we screened two libraries from the National Cancer Institute, namely, the natural product s

178 aracterisation Laboratory (EUNCL) and the US National Cancer Institute Nanotechnology Characterizatio

179 ion of Cancer Treatment and Diagnosis at the National Cancer Institute (National Institutes of Health

180 National Cancer Institute, National Comprehensive Cancer

181 AEs at a conference jointly sponsored by the National Cancer Institute, National Institute of Allergy

182 per la Ricerca sul Cancro, Cancer Australia, National Cancer Institute, National Institute of Health,

183 from June 1, 2012, to July 30, 2016, at the National Cancer Institute, National Institutes of Health

184 itute of Allergy and Infectious Diseases and National Cancer Institute, National Institutes of Health

185 National Cancer Institute, National Institutes of Health

186 nitiative, and Cancer Center Support (Core), National Cancer Institute, National Institutes of Health

187 US National Cancer Institute, National Institutes of Health

188 abetes and Digestive and Kidney Diseases and National Cancer Institute, National Institutes of Health

189 National Cancer Institute, National Institutes of Health

190 Intramural Research Program of the National Cancer Institute, National Institutes of Health

191 National Cancer Institute, National Palliative Care Rese

192 e on Minority Health and Health Disparities; National Cancer Institute; National Heart, Lung, and Blo

193 National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy

194 on on Cancer (CoC) -accredited hospitals and National Cancer Institute (NCI) -designated cancer cente

195 Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reve

196 cells and its antileukemic effectsFUNDINGTHE National Cancer Institute (NCI) and the Institute of Gen

197 s Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mand

198 are it to phantom based MC provided from the National Cancer Institute (NCI) as academic reference.

199 uman Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiati

200 y dataset included patients from an existing National Cancer Institute (NCI) cohort of the CIBMTR dat

201 e postoperative events were graded using the National Cancer Institute (NCI) Common Terminology Crite

202 risk groups on the basis of a combination of National Cancer Institute (NCI) criteria, cytogenetics,

203 t was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule d

204 More than half a century ago, the National Cancer Institute (NCI) established a network of

205 National Cancer Institute (NCI) grants 3P50CA126752 and

206 Finally, for many years agencies such as the National Cancer Institute (NCI) have encouraged the deve

207 Children with newly diagnosed National Cancer Institute (NCI) high-risk B-cell acute l

208 During the COVID-19 pandemic, the National Cancer Institute (NCI) is bringing to bear its

209 The National Cancer Institute (NCI) Mouse Models of Human Ca

210 A National Cancer Institute (NCI) sponsored, multicenter,

211 We used the National Cancer Institute (NCI) Surveillance, Epidemiolo

212 The COG-National Cancer Institute (NCI) TARGET AML initiative as

213 Resources (GSR) is a website provided by the National Cancer Institute (NCI) that aims to help resear

214 Compounds obtained from the National Cancer Institute (NCI) were docked to the recep

215 The US National Cancer Institute (NCI), in collaboration with s

216 n = 0.2 mum) in almost all cell lines of the National Cancer Institute (NCI)-60 cell line screen and

217 n areas that do and do not contain one of 69 National Cancer Institute (NCI)-Designated Cancer Center

218 insurance, and those who received care at a National Cancer Institute (NCI)-designated cancer center

219 ence interval (CI) 1.05-1.16), and care at a National Cancer Institute (NCI)-designated center (OR 1.

220 National Cancer Institute (NCI)-sponsored clinical trial

221 Funding data were obtained from the National Cancer Institute (NCI).

222 e obtained data from the SEER Program of the National Cancer Institute (NCI).

223 driven master protocol initiated with the US National Cancer Institute (NCI).

224 cases in a stage-1 case-only analysis of the National Cancer Institute (NCI, 541 cases with FH and 13

225 Responses were determined by using the 1996 National Cancer Institute (NCI-96) and 2008 Internationa

226 ymphoblastic leukemia between 2004 and 2011 (National Cancer Institute [NCI] standard risk [SR]: AALL

227 ancer Society; Swedish Research Council; and National Cancer Institute (NIH).

228 rt Association; the Margolis Foundation; the National Cancer Institute, NIH (5R00CA218694-03); and th

229 Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH.

230 (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Tria

231 trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Grou

232 city as compared with 37% of patients in the National Cancer Institute of Canada SR2 (CAN-NCIC-SR2: P

233 ng the present analysis, was provided by the National Cancer Institute of National Institutes of Heal

234 National Cancer Institute of the National Institutes of

235 ECOG-ACRIN Cancer Research Group, National Cancer Institute of the National Institutes of

236 US National Cancer Institute of the National Institutes of

237 College of Radiology Imaging Network and the National Cancer Institute of the National Institutes of

238 rly Career Cancer Systems Biologists and the National Cancer Institute of the NIH, focused on the int

239 National Cancer Institute of the US National Institutes

240 A workshop at the National Cancer Institute on May 2, 2016, considered the

241 we summarize cohort studies conducted by the National Cancer Institute on meat and dairy intake in re

242 ogressive urothelial carcinoma enrolled in a National Cancer Institute open-label, nonrandomized, pha

243 All patients were treated at either the National Cancer Institute or the Department of Breast Me

244 e Veterans Affairs Research Program, the NIH/National Cancer Institute (P01CA163227), and the Prostat

245 Using the National Cancer Institute Patterns of Care Studies and l

246 iser Permanente Northern California and U.S. National Cancer Institute Persistence and Progression St

247 f a randomized controlled trial (RCT) by the National Cancer Institute Physicians Data Query and addi

248 National Cancer Institute, private foundations, and inst

249 The National Cancer Institute recently launched its Communit

250 erapy than among the general population, the National Cancer Institute recommends skin self-examinati

251 EORTC QLQ-C30 and EORTC QLQ-CR38, and National Cancer Institute's (NCI) PRO-CTCAE were selecte

252 Top1-mediated DNA cleavage assay and in the National Cancer Institute's 60 cell line cytotoxicity as

253 ide (CL) to permit an evaluation against the National Cancer Institute's 60-cell line panel and allow

254 cancer cases and 12,760 controls within the National Cancer Institute's Breast and Prostate Cancer C

255 used a nested case-control design within the National Cancer Institute's Breast and Prostate Cancer C

256 ance metrics and criteria established by the National Cancer Institute's Clinical Proteomic Tumor Ana

257 severity of adverse events assessed with the National Cancer Institute's Common Terminology Criteria

258 Complications were evaluated with the National Cancer Institute's Common Terminology Criteria

259 ymptomatic AEs using a PRO adaptation of the National Cancer Institute's Common Terminology Criteria

260 urce use, including information found in the National Cancer Institute's Physician Data Query and UpT

261 app-based MT (n = 33) vs. an active control (National Cancer Institute's QuitGuide, n = 34).

262 2012 (N = 5,284) were recruited through the National Cancer Institute's SEER Program.

263 Data were obtained from the National Cancer Institute's SEER registry for all patien

264 The National Cancer Institute's Surveillance, Epidemiology,

265 ormed using an independent data set from the National Cancer Institute's Surveillance, Epidemiology,

266 12 from the 18 US regional registries of the National Cancer Institute's Surveillance, Epidemiology,

267 1, 2004, through December 31, 2005, from the National Cancer Institute's Surveillance, Epidemiology,

268 trospective cohort study using data from the National Cancer Institute's Surveillance, Epidemiology,

269 der (40-84 years) non-Hispanic whites in the National Cancer Institute's Surveillance, Epidemiology,

270 ol of Public Health, Harvard Medical School, National Cancer Institute, SickKids, St Jude Children's

271 ol of Public Health, Harvard Medical School, National Cancer Institute, SickKids, St Jude Children's

272 rsity of Texas MD Anderson Cancer Center and National Cancer Institute Specialized Programs of Resear

273 The National Cancer Institute sponsored a clinical trials pl

274 independent registries and disease-specific, National Cancer Institute-sponsored clinics.

275 dels for HIV-related eligibility criteria in National Cancer Institute-sponsored studies are instruct

276 iew of HIV-related eligibility criteria from National Cancer Institute-sponsored studies.

277 US National Cancer Institute, St Baldrick's Foundation, and

278 A National Cancer Institute summit, held in 2007, on neuro

279 NIDCR support decreased in most years, while National Cancer Institute support increased and approach

280 The model was calibrated to National Cancer Institute Surveillance, Epidemiology, an

281 in 1 of 9 population-based registries of the National Cancer Institute Surveillance, Epidemiology, an

282 nal SNPs, population incidence rate from the National Cancer Institute-Surveillance, Epidemiology, an

283 tion-based case-control study of NHL in four National Cancer Institute-Surveillance, Epidemiology, an

284 , Epidemiology, and End Results registry and National Cancer Institute survey.

285 held on May 4, 2016 with officials from the National Cancer Institute, the FDA, members of the Ameri

286 The National Cancer Institute, the National Heart, Lung, and

287 stitute of Child Health and Development, the National Cancer Institute, the National Institute for Al

288 e in November 2012 in collaboration with the National Cancer Institute, the National Institute on Agi

289 National Cancer Institute, the University of Michigan Ro

290 nstitute of Allergy and Infectious Diseases; National Cancer Institute; the Leukemia and Lymphoma Soc

291 e of AIDS Research; American Cancer Society; National Cancer Institute through a Leidos subcontract;

292 enter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation

293 is one of three pilot projects funded by the National Cancer Institute to explore new approaches to c

294 Supported by the National Cancer Institute UH2/3 CA189908.

295 National Cancer Institute, US Department of Health and H

296 US National Cancer Institute, US National Institutes of Hea

297 National Cancer Institute USA, Eli Lilly, and The Oral C

298 National Cancer Institute, Walther Cancer Institute, Ind

299 oncurrently with a workshop sponsored by the National Cancer Institute, we identified key "drivers" f

300 The National Cancer Institute, which currently supports an a